OA11569A - Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues(GHS) for treating musculoskeletal frailty. - Google Patents
Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues(GHS) for treating musculoskeletal frailty. Download PDFInfo
- Publication number
- OA11569A OA11569A OA1200000346A OA1200000346A OA11569A OA 11569 A OA11569 A OA 11569A OA 1200000346 A OA1200000346 A OA 1200000346A OA 1200000346 A OA1200000346 A OA 1200000346A OA 11569 A OA11569 A OA 11569A
- Authority
- OA
- OAPI
- Prior art keywords
- oxo
- pyridin
- ethyl
- phenyl
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8942498P | 1998-06-16 | 1998-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA11569A true OA11569A (en) | 2004-07-01 |
Family
ID=22217565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200000346A OA11569A (en) | 1998-06-16 | 1999-05-03 | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues(GHS) for treating musculoskeletal frailty. |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1085867A1 (hr) |
| JP (1) | JP2002518328A (hr) |
| KR (1) | KR20010052817A (hr) |
| CN (1) | CN1305378A (hr) |
| AP (1) | AP9901581A0 (hr) |
| AR (1) | AR018868A1 (hr) |
| AU (1) | AU3342099A (hr) |
| BG (1) | BG105128A (hr) |
| BR (1) | BR9911357A (hr) |
| CA (1) | CA2335112A1 (hr) |
| CO (1) | CO5070586A1 (hr) |
| EA (1) | EA200001189A1 (hr) |
| GT (1) | GT199900083A (hr) |
| HR (1) | HRP20000857A2 (hr) |
| HU (1) | HUP0102395A2 (hr) |
| ID (1) | ID26726A (hr) |
| IL (1) | IL139587A0 (hr) |
| IS (1) | IS5727A (hr) |
| MA (1) | MA26648A1 (hr) |
| NO (1) | NO20006381D0 (hr) |
| OA (1) | OA11569A (hr) |
| PA (1) | PA8472101A1 (hr) |
| PE (1) | PE20000633A1 (hr) |
| PL (1) | PL345064A1 (hr) |
| SK (1) | SK18902000A3 (hr) |
| TN (1) | TNSN99118A1 (hr) |
| UY (1) | UY25557A1 (hr) |
| WO (1) | WO1999065488A1 (hr) |
| ZA (1) | ZA993973B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1004306A3 (en) * | 1998-08-06 | 2000-06-07 | Pfizer Products Inc. | Estrogen agonists/antagonists |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| AP2001002264A0 (en) | 2000-08-30 | 2001-09-30 | Pfizer Prod Inc | Sustained release formulations for growth hormone secretagogues. |
| DK1460969T3 (da) * | 2001-11-29 | 2008-09-01 | Gtx Inc | Forebyggelse og behandling af ved androgen-berövelse fremkaldt osteoporose |
| US7524866B2 (en) | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| ES2602789T3 (es) | 2007-02-09 | 2017-02-22 | Ocera Therapeutics, Inc. | Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
-
1999
- 1999-05-03 HU HU0102395A patent/HUP0102395A2/hu unknown
- 1999-05-03 KR KR1020007014140A patent/KR20010052817A/ko not_active Application Discontinuation
- 1999-05-03 OA OA1200000346A patent/OA11569A/en unknown
- 1999-05-03 PL PL99345064A patent/PL345064A1/xx unknown
- 1999-05-03 JP JP2000554368A patent/JP2002518328A/ja active Pending
- 1999-05-03 EA EA200001189A patent/EA200001189A1/ru unknown
- 1999-05-03 SK SK1890-2000A patent/SK18902000A3/sk unknown
- 1999-05-03 CA CA002335112A patent/CA2335112A1/en not_active Abandoned
- 1999-05-03 CN CN99807381A patent/CN1305378A/zh active Pending
- 1999-05-03 AU AU33420/99A patent/AU3342099A/en not_active Abandoned
- 1999-05-03 BR BR9911357-0A patent/BR9911357A/pt not_active Application Discontinuation
- 1999-05-03 IL IL13958799A patent/IL139587A0/xx unknown
- 1999-05-03 WO PCT/IB1999/000796 patent/WO1999065488A1/en not_active Application Discontinuation
- 1999-05-03 EP EP99914723A patent/EP1085867A1/en not_active Withdrawn
- 1999-05-03 ID IDW20002604A patent/ID26726A/id unknown
- 1999-05-07 PA PA19998472101A patent/PA8472101A1/es unknown
- 1999-06-10 AP APAP/P/1999/001581A patent/AP9901581A0/en unknown
- 1999-06-11 PE PE1999000522A patent/PE20000633A1/es not_active Application Discontinuation
- 1999-06-11 UY UY25557A patent/UY25557A1/es not_active Application Discontinuation
- 1999-06-14 GT GT199900083A patent/GT199900083A/es unknown
- 1999-06-15 AR ARP990102847A patent/AR018868A1/es not_active Application Discontinuation
- 1999-06-15 ZA ZA9903973A patent/ZA993973B/xx unknown
- 1999-06-15 MA MA25622A patent/MA26648A1/fr unknown
- 1999-06-15 TN TNTNSN99118A patent/TNSN99118A1/fr unknown
- 1999-06-16 CO CO99037624A patent/CO5070586A1/es unknown
-
2000
- 2000-11-24 IS IS5727A patent/IS5727A/is unknown
- 2000-12-14 HR HR20000857A patent/HRP20000857A2/hr not_active Application Discontinuation
- 2000-12-14 NO NO20006381A patent/NO20006381D0/no not_active Application Discontinuation
-
2001
- 2001-01-08 BG BG105128A patent/BG105128A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA200001189A1 (ru) | 2001-06-25 |
| NO20006381L (no) | 2000-12-14 |
| PL345064A1 (en) | 2001-11-19 |
| BR9911357A (pt) | 2001-03-13 |
| AR018868A1 (es) | 2001-12-12 |
| ID26726A (id) | 2001-02-01 |
| PA8472101A1 (es) | 2000-09-29 |
| IS5727A (is) | 2000-11-24 |
| KR20010052817A (ko) | 2001-06-25 |
| AP9901581A0 (en) | 1999-06-30 |
| TNSN99118A1 (fr) | 2005-11-10 |
| WO1999065488A1 (en) | 1999-12-23 |
| NO20006381D0 (no) | 2000-12-14 |
| MA26648A1 (fr) | 2004-12-20 |
| BG105128A (en) | 2001-11-30 |
| IL139587A0 (en) | 2002-02-10 |
| AU3342099A (en) | 2000-01-05 |
| JP2002518328A (ja) | 2002-06-25 |
| EP1085867A1 (en) | 2001-03-28 |
| PE20000633A1 (es) | 2000-07-26 |
| ZA993973B (en) | 2000-12-15 |
| SK18902000A3 (sk) | 2001-12-03 |
| CA2335112A1 (en) | 1999-12-23 |
| GT199900083A (es) | 2000-12-05 |
| HUP0102395A2 (hu) | 2001-11-28 |
| CN1305378A (zh) | 2001-07-25 |
| HRP20000857A2 (en) | 2001-10-31 |
| UY25557A1 (es) | 2001-01-31 |
| CO5070586A1 (es) | 2001-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1414486B1 (en) | Use of glp-2 in combination with another therapeutic agent in bone-related disorders | |
| US7632813B2 (en) | Bone densifying agent characterized by use of cathepsin K inhibitor with PTH | |
| JP2003528135A (ja) | 糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法 | |
| JPH11180926A (ja) | 骨粗しょう症用化合物 | |
| JP2000514840A (ja) | 成長ホルモン分泌促進物質としての置換ジペプチドの酒石酸塩 | |
| KR20140084303A (ko) | 소아 담즙울체성 간 질환 치료용 담즙산 재순환 억제제 | |
| CN109922812A (zh) | 减少与甲状腺相关的副作用的方法 | |
| HRP980356A2 (en) | Prostaglandin agonists | |
| US20050065133A1 (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist | |
| US20050065180A1 (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a growth hormone secretagogue | |
| OA11569A (en) | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues(GHS) for treating musculoskeletal frailty. | |
| OA11566A (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone. | |
| US20020002137A1 (en) | Combination of growth hormone secretagogues and antidepressants | |
| OA11505A (en) | Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretagogues (GHS) for treating musculoskeletal frailty. | |
| EP1490055A1 (en) | Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension | |
| CZ20004680A3 (cs) | Terapeutické kombinace (selektivních) modulátorů estrogenního receptorů (ŠERM) a prostředků podporujících sekreci růstového hormonu (GHS) pro léčbu muskuloskeletární fragility | |
| US6284773B1 (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2 | |
| MXPA00012628A (en) | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty | |
| CZ20004679A3 (cs) | Terapeutické kombinace (selektivních) modulátorů estrogenního receptoru (ŠERM) a prostředků podporujících sekreci růstového hormonu (GHS) pro léčbu muskuloskeletární fragility | |
| MXPA00012727A (en) | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty | |
| EA008927B1 (ru) | Применение производных 2h-[1,3]оксазино[3,2-a]индола для лечения невропатической боли | |
| MXPA99005564A (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2 |